Your browser doesn't support javascript.
loading
Structure-Activity Relationship of USP5 Inhibitors.
Mann, Mandeep K; Zepeda-Velázquez, Carlos A; González-Álvarez, Héctor; Dong, Aiping; Kiyota, Taira; Aman, Ahmed M; Loppnau, Peter; Li, Yanjun; Wilson, Brian; Arrowsmith, Cheryl H; Al-Awar, Rima; Harding, Rachel J; Schapira, Matthieu.
Afiliação
  • Mann MK; Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS South Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada.
  • Zepeda-Velázquez CA; Department of Pharmacology and Toxicology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.
  • González-Álvarez H; Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.
  • Dong A; Department of Pharmacology and Toxicology, University of Toronto, 1 King's College Circle, Toronto, Ontario M5S 1A8, Canada.
  • Kiyota T; Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.
  • Aman AM; Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS South Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada.
  • Loppnau P; Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.
  • Li Y; Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.
  • Wilson B; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada.
  • Arrowsmith CH; Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS South Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada.
  • Al-Awar R; Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS South Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada.
  • Harding RJ; Ontario Institute for Cancer Research, 661 University Avenue, Toronto, Ontario M5G 0A3, Canada.
  • Schapira M; Structural Genomics Consortium, University of Toronto, 101 College Street, MaRS South Tower, Suite 700, Toronto, Ontario M5G 1L7, Canada.
J Med Chem ; 64(20): 15017-15036, 2021 10 28.
Article em En | MEDLINE | ID: mdl-34648286
ABSTRACT
USP5 is a deubiquitinase that has been implicated in a range of diseases, including cancer, but no USP5-targeting chemical probe has been reported to date. Here, we present the progression of a chemical series that occupies the C-terminal ubiquitin-binding site of a poorly characterized zinc-finger ubiquitin binding domain (ZnF-UBD) of USP5 and competitively inhibits the catalytic activity of the enzyme. Exploration of the structure-activity relationship, complemented with crystallographic characterization of the ZnF-UBD bound to multiple ligands, led to the identification of 64, which binds to the USP5 ZnF-UBD with a KD of 2.8 µM and is selective over nine proteins containing structurally similar ZnF-UBD domains. 64 inhibits the USP5 catalytic cleavage of a di-ubiquitin substrate in an in vitro assay. This study provides a chemical and structural framework for the discovery of a chemical probe to delineate USP5 function in cells.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Endopeptidases / Inibidores Enzimáticos Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Endopeptidases / Inibidores Enzimáticos Idioma: En Ano de publicação: 2021 Tipo de documento: Article